<DOC>
	<DOC>NCT02166021</DOC>
	<brief_summary>The purpose of this study is to to evaluate the optimal dosage and the way of administration of autologous mesenchymal bone marrow stem cells (MSC) either in maximal proximity of the lesions in the CNS or by intrathecal injection to the CSF.</brief_summary>
	<brief_title>Optimal Administration Mode of Autologous Mesenchymal Bone Marrow Stem Cells in Active and Progressive Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>1. Consenting patients fulfilling the Poser's clinical criteria for definite MS 2. Age: 2565, males and females 3. Duration of disease: &gt;3 years 4. Progressive form of MS (RPMS, SPMS) 5. EDSS score of 3.0 6.5 6. Failure to the currently available, registered first and second line immunomodulatory treatments 7. Evidence for new activity of MS during the 3 months before the injection of MSC. 1. Patients who were treated with cytotoxic medications during the last 3 months prior to the inclusion. 2. Patients suffering from significant cardiac, renal or hepatic failure or any other disease that may risk the patient or interfere with the ability to interpret the results 3. Patients with active infections 4. Patients with severe cognitive decline or inability to understand and sign the informed consent</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Multiple Sclerosis (MS)</keyword>
	<keyword>Stem Cells</keyword>
</DOC>